Miniatura

Fitxers

662594.pdf (6.55 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2013-10-01

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/102129

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1172/JCI66764

Resum

Aberrant regulation of the erythroblastosis oncogene B (ErbB) family of receptor tyrosine kinases (RTKs) and their ligands is common in human cancers. ErbB3 is required in luminal mammary epithelial cells (MECs) for growth and survival. Since breast cancer phenotypes may reflect biological traits of the MECs from which they originate, we tested the hypothesis that ErbB3 drives luminal breast cancer growth. We found higher ERBB3 expression and more frequent ERBB3 gene copy gains in luminal A/B breast cancers compared with other breast cancer subtypes. In cell culture, ErbB3 increased growth of luminal breast cancer cells. Targeted depletion of ErbB3 with an anti-ErbB3 antibody decreased 3D colony growth, increased apoptosis, and decreased tumor growth in vivo. Treatment of clinical breast tumors with the antiendocrine drug fulvestrant resulted in increased ErbB3 expression and PI3K/mTOR signaling. Depletion of ErbB3 in fulvestrant-treated tumor cells reduced PI3K/mTOR signaling, thus decreasing tumor cell survival and tumor growth. Fulvestrant treatment increased phosphorylation of all ErbB family RTKs; however, phospho-RTK upregulation was not seen in tumors treated with both fulvestrant and anti-ErbB3. These data indicate that upregulation of ErbB3 in luminal breast cancer cells promotes growth, survival, and resistance to fulvestrant, thus suggesting ErbB3 as a target for breast cancer treatment.

Matèries

Càncer de mama, Receptors d'hormones, Estrògens, Medicaments antineoplàstics, Expressió gènica

Matèries (anglès)

Breast cancer, Hormone receptors, Estrogen, Antineoplastic agents, Gene expression

Citació

Col·leccions

Articles publicats en revistes (Medicina)

Citació

MORRISON, Meghan m., HUTCHINSON, Katherine, WILLIAMS, Michelle m., STANFORD, Jamie c., BALKO, Justin m., YOUNG, Christian, KUBA, Maria g., SÁNCHEZ, Violeta, WILLIAMS, Andrew j., HICKS, Donna j., ARTEAGA, Carlos l., PRAT APARICIO, Aleix, PEROU, Charles m., EARP, H. shelton, MASSARWEH, Suleiman, COOK, Rebecca s.. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. _Journal of Clinical Investigation_. 2013. Vol. 123, núm. 10, pàgs. 4329-4343. [consulta: 24 de gener de 2026]. ISSN: 0021-9738. [Disponible a: https://hdl.handle.net/2445/102129]

Exportar metadades

JSON - METS

Compartir registre